SLC5A2 and kidney disorder: For instance, large-scale clinical trials using another SGLT-2 inhibitor such as canagliflozin and dapagliflozin have shown that SGLT2 inhibitors reduce the risk of kidney disease progression, independent of their glucose-lowering effects [21, 22].